

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

1. *(Currently amended):* A method for ~~prophylaxis or~~ treatment of benign prostatic hypertrophy hyperplasia (BPH) comprising administering ~~an~~ a therapeutically effective amount of lonidamine ~~or a lonidamine analog~~ to a human subject in need of such treatment.
2. *(Currently amended)* The method of claim 1 comprising administering lonidamine to the subject at a dose of 150 mg administered orally once per day for one month.
3. *(Original):* The method of claim 1 wherein the subject is not being treated for cancer.
4. *(Currently amended):* The method of claim 3 wherein the subject is not diagnosed ~~with~~ as having cancer.
5. *(Currently amended):* The method of claim 1 wherein the subject has a serum PSA greater than ~~about~~ 2 ng/ml.
6. *(Currently amended):* The method of claim 5 wherein the subject has a serum PSA less than ~~about~~ 10 ng/ml.
7. *(Currently amended):* The method of claim 1 wherein ~~the~~ lonidamine ~~or lonidamine analog~~ is administered in combination with another treatment for BPH.
8. *(Original):* The method of claim 7 wherein the other treatment is: a) administration of an alpha-blocker; b) administration of a 5-alpha-reductase inhibitor; c) administration of zinc; or d) a surgical procedure.
9. *(Currently amended):* The method of claim 1 2, wherein lonidamine is administered at least once per week for at least 4 weeks.

10. (*Currently amended*): The method of claim 1 2, wherein lonidamine is administered at least once daily for at least five days.

11. (*Currently amended*): The method of claim 9 wherein the daily dose is in the range of ~~about 1 mg and about~~ to 300 mg.

12. (*Currently amended*): The method of claim 9 wherein the daily dose is between ~~about~~ 300 mg and ~~about~~ 5 grams.

13. (*Original*): The method of claim 9 wherein the daily dose is 150 mg p.o. TID.

14. (*Currently amended*): The method of claim 1, wherein lonidamine is administered as a unit dose oral pharmaceutical composition that is a sustained-release formulation comprising from ~~about 1 mg to about~~ 2000 mg lonidamine.

15. (*Original*): The method of claim 1 wherein, when compared to a baseline prior to the initiation of treatment, the subject's a) AUASI or IPSS score is decreased by at least 3 points; b) prostate size has decreased by at least about 20%; and/or c) serum PSA levels have decreased by at least about 20%, when determined on or after 60 days after the initiation of treatment.

16. (*Currently amended*): A method for treating BPH comprising (a) diagnosing BPH in a patient, (b) administering lonidamine ~~or a lonidamine analog~~ to the patient and (c) determining whether one or more manifestations of BPH are reduced in said patient.

17. (*Currently amended*): A method for treating BPH comprising (a) administering lonidamine ~~or a lonidamine analog~~ to a patient diagnosed with BPH and (b) determining whether one or more manifestations of BPH are reduced in said patient.

18 - 20 (*Cancelled*)

21. (*New*): The method of claim 11 wherein the daily dose is in the range of 5 mg to 70 mg.

22. (*New*): The method of claim 10 wherein the daily dose is in the range of 1 mg to 300 mg.

23. (New): The method of claim 22 wherein the daily dose is in the range of 5 mg to 70 mg.
24. (New): A method for reducing a symptom associated with BPH comprising administering lonidamine to a human subject in need of such treatment, wherein the subject is not under treatment for cancer or diagnosed with cancer.
25. (New): The method of claim 24, wherein lonidamine is administered at least once daily for at least five days.
26. (New): The method of claim 25 wherein the daily dose is in the range of 1 mg to 300 mg.
27. (New): The method of claim 26 wherein the daily dose is in the range of 5 mg to 70 mg.